[go: up one dir, main page]

HK1050197A1 - Dipeptide nitrile cathepsin k inhibitors - Google Patents

Dipeptide nitrile cathepsin k inhibitors Download PDF

Info

Publication number
HK1050197A1
HK1050197A1 HK03102397A HK03102397A HK1050197A1 HK 1050197 A1 HK1050197 A1 HK 1050197A1 HK 03102397 A HK03102397 A HK 03102397A HK 03102397 A HK03102397 A HK 03102397A HK 1050197 A1 HK1050197 A1 HK 1050197A1
Authority
HK
Hong Kong
Prior art keywords
cyanomethyl
residue
piperazin
sub
methanol
Prior art date
Application number
HK03102397A
Other languages
English (en)
Chinese (zh)
Other versions
HK1050197B (en
Inventor
Missbach Martin
Original Assignee
诺瓦提斯公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 诺瓦提斯公司 filed Critical 诺瓦提斯公司
Publication of HK1050197A1 publication Critical patent/HK1050197A1/xx
Publication of HK1050197B publication Critical patent/HK1050197B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
HK03102397.2A 2000-02-10 2001-02-08 Dipeptide nitrile cathepsin k inhibitors HK1050197B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0003111.2A GB0003111D0 (en) 2000-02-10 2000-02-10 Organic compounds
GB0003111.2 2000-02-10
PCT/EP2001/001359 WO2001058886A1 (en) 2000-02-10 2001-02-08 Dipeptide nitrile cathepsin k inhibitors

Publications (2)

Publication Number Publication Date
HK1050197A1 true HK1050197A1 (en) 2003-06-13
HK1050197B HK1050197B (en) 2005-05-13

Family

ID=

Also Published As

Publication number Publication date
RU2005108133A (ru) 2006-09-10
CO5261578A1 (es) 2003-03-31
PT1254124E (pt) 2008-11-03
AU4642601A (en) 2001-08-20
CN1398260A (zh) 2003-02-19
RU2293732C2 (ru) 2007-02-20
HUP0300148A2 (en) 2003-05-28
US20030203919A1 (en) 2003-10-30
CN1636980A (zh) 2005-07-13
CA2396158C (en) 2010-02-02
KR100544553B1 (ko) 2006-01-24
KR20020072310A (ko) 2002-09-14
JP2003522764A (ja) 2003-07-29
ES2310177T3 (es) 2009-01-01
BR0108118A (pt) 2003-02-25
RU2002123350A (ru) 2004-01-10
EP1254124B1 (en) 2008-07-30
CA2396158A1 (en) 2001-08-16
HUP0300148A3 (en) 2005-04-28
NO20023780L (no) 2002-08-09
SK11462002A3 (sk) 2003-01-09
DE60135087D1 (de) 2008-09-11
NZ519940A (en) 2004-02-27
GB0003111D0 (en) 2000-03-29
AU764334B2 (en) 2003-08-14
TR200201752T2 (tr) 2002-10-21
ZA200206218B (en) 2003-08-05
PL200119B1 (pl) 2008-12-31
NO20023780D0 (no) 2002-08-09
US20070191392A1 (en) 2007-08-16
AR029466A1 (es) 2003-07-02
US6642239B2 (en) 2003-11-04
JP3942895B2 (ja) 2007-07-11
RU2265601C2 (ru) 2005-12-10
PL357901A1 (en) 2004-07-26
WO2001058886A1 (en) 2001-08-16
MY122826A (en) 2006-05-31
CN1183122C (zh) 2005-01-05
US20050267129A1 (en) 2005-12-01
EP1254124A1 (en) 2002-11-06
TWI258473B (en) 2006-07-21
CZ20022721A3 (cs) 2002-11-13
US20010016207A1 (en) 2001-08-23
PE20020220A1 (es) 2002-03-25
ATE402930T1 (de) 2008-08-15
MXPA02007768A (es) 2002-10-11
IL150406A0 (en) 2002-12-01

Similar Documents

Publication Publication Date Title
CN1183122C (zh) 二肽腈组织蛋白酶k抑制剂
CN1093125C (zh) 硫酰胺-金属蛋白酶抑制剂
CN1280288C (zh) 作为1型纤溶酶原激活物抑制剂(pai-1)的抑制剂的取代萘基吲哚衍生物
CN1549717A (zh) 用于治疗炎症和其它疾病、具有2-氰基-4-氨基嘧啶结构和组织蛋白酶k抑制活性的半胱氨酸蛋白酶抑制剂
CN1253474A (zh) 磺酰基二价芳基或杂芳基异羟肟酸化合物
CN1165815A (zh) 酚化合物及其制备方法
CN1261885A (zh) 2-取代的4,5-二芳基咪唑
CN1168709C (zh) 作为基质金属蛋白酶抑制剂的β-磺酰基异羟肟酸的α-羟基、-氨基和卤代衍生物
CN1950323A (zh) Crth2受体拮抗剂
CN1362954A (zh) 氨基磺酸基异羟肟酸金属蛋白酶抑制剂
CN1922162A (zh) 烷基哌嗪-和烷基高哌嗪-羧酸酯衍生物、其制备方法及其作为faah酶抑制剂的用途
CN1460101A (zh) 抑制因子Xa活性的新化合物
CN1922138A (zh) 芳氧基烷基氨基甲酸酯类衍生物,它们的制备方法与治疗用途
CN1500085A (zh) 降低脂质的联苯基甲酰胺
CN1127488C (zh) 具有生长激素释放特性的化合物
CN1159318C (zh) 新的金属蛋白酶抑制剂、其制备方法及含有其的药物组合物
CN1516689A (zh) 制备哌啶衍生物非索非那定的方法
CN1105711C (zh) 嘧啶衍生物
HK1050197B (en) Dipeptide nitrile cathepsin k inhibitors
HK1077820A (en) Dipeptide nitrile cathepsin k inhibitors
CN1373751A (zh) α-氨基-β-磺酰基异羟肟酸化合物
HK1067055A (en) Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases
CN1968920A (zh) 三环芳香族亚硫酰基衍生物和双苯基亚硫酰基衍生物
HK1024915A (en) Sulfamide-metalloprotease inhibitors

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20090208